Syneos Health (NASDAQ:SYNH – Get Rating) released its quarterly earnings data on Friday. The company reported $1.01 EPS for the quarter, beating the consensus estimate of $0.95 by $0.06, MarketWatch Earnings reports. The business had revenue of $1.34 billion during the quarter, compared to the consensus estimate of $1.32 billion. Syneos Health had a net margin of 4.50% and a return on equity of 12.69%. The business’s revenue was up 10.5% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.66 EPS. Syneos Health updated its FY22 guidance to $5.05-5.25 EPS.
Shares of Syneos Health stock traded down $0.58 during mid-day trading on Monday, hitting $72.51. 1,480 shares of the stock were exchanged, compared to its average volume of 734,244. Syneos Health has a twelve month low of $66.77 and a twelve month high of $104.18. The stock has a market capitalization of $7.44 billion, a price-to-earnings ratio of 31.64 and a beta of 1.84. The company has a 50-day simple moving average of $78.80 and a 200 day simple moving average of $88.86. The company has a current ratio of 1.07, a quick ratio of 1.07 and a debt-to-equity ratio of 0.82.
SYNH has been the subject of several recent analyst reports. Jefferies Financial Group downgraded shares of Syneos Health from a “buy” rating to a “hold” rating and lowered their target price for the company from $101.00 to $75.00 in a research note on Monday, April 25th. Zacks Investment Research upgraded shares of Syneos Health from a “sell” rating to a “hold” rating and set a $95.00 target price on the stock in a research report on Monday, January 17th. StockNews.com assumed coverage on shares of Syneos Health in a research report on Thursday, March 31st. They set a “hold” rating on the stock. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Syneos Health in a research note on Monday, April 11th. They issued a “buy” rating and a $102.00 price target on the stock. Finally, Barclays cut their target price on shares of Syneos Health from $115.00 to $105.00 and set an “overweight” rating on the stock in a research note on Thursday, January 27th. Four analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $100.33.
About Syneos Health (Get Rating)
Syneos Health, Inc provides biopharmaceutical outsourcing solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers services for the development of diagnostics, drugs, biologics, devices, and digital therapeutics in the Phase I to IV of clinical development.
- Get a free copy of the StockNews.com research report on Syneos Health (SYNH)
- Is The FOMC About To Spark A Massive Stock Market Correction?
- Knight-Swift Transportation Stock is a Logistics Winner
- Enphase Energy Has a Sunny Future With Some Clouds in the Short Term
- Why is Chevron Stock Falling After Strong Earnings?
- MarketBeat: Week in Review 4/25 – 4/29
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.